Higher ed institutions are using Otter’s AI technology to transfer lectures into notes – TechRepublic

The company says its speech technology can help students and educators avoid video conferencing fatigue.

Image: Getty Images/iStockphoto

The COVID-19 pandemic has challenged universities to fundamentally reexamine how their students learn, with remote learning creating a new frontier for their educators. Since in-person learning isn't viable for every student, collaboration has become more important than ever. But the video meetings that have now taken over how people work and socialize are causing the phenomenon known as "Zoom fatigue," although it applies to every video conferencing platform.That may foster a new trend on college campuses this fall: Turning spoken lectures into highly accurate lecture notes. Otter.ai's Otter for Education AI speech technology aims to give both lecturers and students the ability to avoid Zoom call information overload, and more accurate notes to students if they miss a class, the company said.SEE: Microsoft Teams and Skype users can now chat together

Otter for Education is being used by over 100,000 students for remote learning and academic accessibility purposes, and can be used in a virtual, onsite or hybrid setting, according to the company. The offering is available over Zoom and other online video lecturing platforms.The goal of Otter's technology is to boost remote classroom collaboration between teachers and students. The technology includes functionality for:

Live comments: During lessons, students are able to view a live interactive transcript and can raise questions by adding comments during a lesson to seek clarification or more information from their teacher. This is an especially important feature when a lecture is conducted over video conferencing technology and educators' interactions with a full class of remote students could be minimized.

Keyword search: Accurate, transcribed lecture notes can be searched by keywords. In addition, Otter auto-generates a collection of keywords at the top of each lecture transcript. Students can find what they think is the most valuable educational information and can follow up post-lecture with further questions and clarifications from their teacher.

Embedded educational material: Additional educational material such as slides, and images can also be embedded into transcripts to aid students' learning experience.

Otter generates smart notes that sync audio, text, and images. Users can search, play, edit, organize, and share meeting notes from any device via the Otter Voice Meeting Notes app.

California State University (CSU), Chico is deploying Otter for Education to its entire teaching faculty for the fall semester. Faculty members using Otter for Education will capture and share lecture notes in real time with their students, the school said.

"Learning at CSU is evolving quickly due to the current environment. With this full rollout of Otter's technology, our faculty can now capture and share lecture notes in real time with their students," said Jeremy Olguin, accessible technology manager at CSU, in a statement.

CSU aims to empower its faculty to help all students receive a better learning experience and the flexibility for them to access the changing learning environment in a way that's most efficient and effective for them, Olguin said. "This is the challenge facing the vast majority of learning institutions right now, especially with lectures likely to be taking place in a hybrid mix of on-site and virtual classrooms for the foreseeable future."

Warwick Business School in the UK is using Otter for Education for its online MBA program, as well as its joint global master's program in central banking, run in collaboration with the Bank of England. Teachers are relying on video content to deliver online lessons and Otter provides accurate transcripts to accompany each video, said Dot Powell, director of teaching and learning enhancement at Warwick, in a statement.

"This is proving to be crucial to the learning experience for our online students as it is helping us to create more useful educational resources for them and receives universally good feedback from students."

Peer note taking in education has long been plagued with challenges, as students were dependent on others for the quality, consistency, interpretation, and timeliness of their notes. Otter is being used by several academic institutions for students who require academic accommodations, including UCLA as well as other universities, community colleges, and Ivy League colleges in the US and abroad, the company said.

"UCLA recognized we needed to offer our students with learning disabilities more control over their academic accommodations. We looked beyond peer note takers for a highly accurate, reliable, and easy-to-use app," said Dr. Nickey Woods, an assistant dean and former director of the Center for Accessibility at UCLA, in a statement.

"Otter Voice Meeting Notes empowers our students with automated live transcription, removes their dependency on others, and enables them to access the learning environment in a way that's most efficient for them."This enables students to actively engage in lectures and study groups instead of focusing on note taking, he said.

Otter for Education is also being used by students requiring academic assistance, especially the hard of hearing and deaf communities at Southern Utah University, according to Carmen R. Alldredge, director of disability services."The COVID-19 pandemic and new mask requirements pose additional challenges for students who also relied on reading lips, as both teachers and fellow students now wear face coverings,'' said Alldredge, in a statement. "Otter has become even more invaluable during this uncertain time to ensure an enhanced education environment for our students."

Learn the latest news and best practices about data science, big data analytics, and artificial intelligence. Delivered Mondays

Read more:

Higher ed institutions are using Otter's AI technology to transfer lectures into notes - TechRepublic

The Collaboration Market: The Role of AI and Disruption – UC Today

Download the Collaboration Market Guide

Video collaboration has emerged as one of the most crucial tools in our communication kit for the modern workplace. As trends like remote and distance working continue to gain speed, video collaboration ensures that team members can maintain crucial connections at a distance. Not only can we communicate freely through video collaboration, but we can also access essential aspects of human connectivity that cant be unlocked with other types of communication, such as body language.

As the demand for video collaboration technology has increased, so too has the need for innovative new tools and features that make this method of discussion more appealing. According to Frost and Sullivan, AI is beginning to bring more reliability and productivity into the meeting room. Virtual assistants can take notes or schedule follow-up meetings with nothing but a voice command.

At the same time, artificial intelligence and bots can transcribe and translate conversations between global team members in seconds, while making the meeting room safer with tools like biometric security. So, whats driving video collaboration forward in 2020?

Artificial intelligence is beginning to play a role in various aspects of our lives. In the office, a voice-enabled smart assistant can arrange meetings and take notes for us in seconds. In the meeting room, AI-driven devices can make sessions run more efficiently by automating tasks like rescheduling calls or sending crucial notifications. AI assistants can even suggest which resources or documents a person may need for a meeting and make them available to access when the conference begins.

Artificial intelligence with natural language processing also improves video collaboration applications in various ways. It can facilitate the automatic transcription or translation of meetings, ensuring that people from around the world can collaborate more efficiently. AI can also improve audio quality by automatically detecting echo and minimizing background noise.

Some businesses are even bringing AI into the video collaboration space with computer vision, helping to frame meeting participants and ensure that everyone can appears clearly. Some tools can even ensure that whiteboards and presentation screens always get enough attention in a video.

Its not just the arrival of new bots and assistants in the collaboration space thats changing the way that we work together. Video collaboration is also affected by the transformation of the meeting spaces that we work in. Ad-hoc huddle rooms and more impromptu spaces are overtaking large board rooms and complicated video meeting environments are being quickly replaced by.

Huddle rooms allow employees to tap into high-quality meeting environments within a matter of minutes. There are video collaboration software and hardware kits that come with plug and play functionality today, so that team members can instantly start a meeting, without having to wait for set-up help from an IT expert.

Advanced and flexible new meeting room spaces ensure that employees from all backgrounds can still enjoy efficient and effective collaboration experiences. Anywhere can now become a meeting space, from a shared environment in a co-working space, to a home environment, or a small spare office in the workplace. AI can even make these spaces more effective by enabling things like blurred backgrounds that eliminate distractions in a busy setting or using noise features to improve the clarity of a users voice.

The video conferencing market alone will be worth around $6.7 billion by 2025.

While the world is beginning to see the benefits of video collaboration at an incredible scale, its important to remember that any new technology does come with challenges. For instance, now that team members can tap into a video meeting from anywhere in the world, there are security and compliance issues to consider.

Business leaders will need to ensure that the right policies are in place to stop team members from signing into dangerous applications and websites using business credentials. VPNs and other security measures may need to be implemented for those who want to join a meeting from an environment with a less secure connection. Just like bringing external devices into the office environment requires a BYOD policy, taking video collaboration outside of the traditional office will require its own protection measures. Business leaders will need to:

Embracing the age of visual communication means making it as easy as possible for your team members to access the tools that they need to interact with. Choosing video collaboration tools that offer things like one-click join facilities, and the ability to dial in from any phone could be an excellent way to get started. Some companies are even using strategies like Microsoft Teams with Direct Routing to ensure that their employees can get all the benefits of their favourite collaboration tools, without having to switch to a new phone service provider.

However, theres more to consider when it comes to ensuring adoption than simplicity. Businesses will also need to think about how theyre going to ensure that their video collaboration strategy works with the rest of the tools that their teams use every day.

Interoperability is often a crucial consideration in ensuring adoption. Creating an environment where your employees can start a video meeting naturally from within the applications that theyre using to connect with coworkers already will make it much easier for video to become a part of your culture.

Most business leaders and technology experts agree that the future is in visual communications. From a collaboration perspective, video gives team members an excellent way to work with each other face-to-face, no matter where they are. In a time when remote and distance working are becoming more popular, video is the only way to preserve the crucial intimate human connections and facial expressions that exist in real-life interactions.

However, preparing for the implementation of visual communication and collaborations in your business means considering a range of things, from how youre going to ensure adoption, to how you can maintain security and compliance.

If you havent started planning for a visual future yet, now is the time to start.

Download the Collaboration Market Guide

Excerpt from:

The Collaboration Market: The Role of AI and Disruption - UC Today

Artificial Intelligence (AI) in Automotive – Market Share Analysis and Research Report by 2025 – CueReport

Latest updates on Artificial Intelligence (AI) in Automotive market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in addition to the market share analysis and the contribution of the prominent contenders toward the overall industry.0

- With the dynamically changing technology landscape in the automotive sector, an increasing number of automobile manufacturers are focusing on integrating semi-autonomous and fully-autonomous technologies into their vehicles

Artificial Intelligence (AI) in Automotive market is projected to surpass USD 12 billion by 2026. The market growth is attributed to the steadily growing uptake of driver assistance technologies for increasing driving comfort and ensuring safe driving experience. Consumers are increasingly exhibiting a positive attitude toward AI-powered vehicle driving systems, creating new avenues for market growth. Automotive manufacturers are capitalizing on the steadily growing industry by introducing new features in their vehicles including automated parking, lane assistance, driver behavior monitoring, and adaptive cruise control. For instance, in October 2019, Toyota announced the launch of level-4 driver assistance systems for enabling automated valet parking in its upcoming cars. The technology is developed in conjunction with Panasonic and is built with inexpensive sensors, offering affordable parking assistance solutions to Toyota's customers.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24675

- Machine learning solutions are witnessing a sustained rise in adoption, enabling AI systems to predict and decide driving patterns in dense traffic. With vastly improved neural network technologies, machine learning can achieve near human driving behavior without external assistance.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24675

- Technology providers including NVIDIA, Intel, and AMD are continuously upgrading their solutions and offering energy-efficient hardware, enabling AI technologies with low power consumption

- Sophisticated onboard AI systems are providing real-time connectivity between vehicle & driver, enabling safe driving and reducing driver fatigue by suggesting resting periods & controlling car navigation during driver distraction

- The growing interest of government agencies in adopting autonomous mobility for reducing traffic accidents and improving traffic management is creating a positive outlook for the industry

- Some of the leading market players are Alphabet Inc., Audi AG, BMW AG, Daimler AG, Didi Chuxing, Ford Motor Company, General Motors Company, Harman International Industries, Inc., Honda Motor Co., Ltd., IBM Corporation, Intel Corporation, Microsoft Corporation, NVIDIA Corporation, Qualcomm Inc., Tesla, Inc., Toyota Motor Corporation, Uber Technologies, Inc., Volvo Car Corporation, and Xilinx Inc.

- AI platform providers are focusing on strategic collaboration and long-term contracts with automotive manufacturers to gain market share

The hardware segment held majority of the market with over 60% share in 2019 and is expected to continue its dominance over the forecast timespan. This is attributed to the increasing adoption of automotive AI components for implementation of AI solutions. Energy-efficient System-on-Chips (SoCs) and dedicated AI GPUs are assisting enterprises in deploying highly sophisticated onboard computers with robust computing power. In July 2019, Intel launched Pohoiki Beach, a new AI-enabled chip, which features 8 million neural networks and can reach up to 10,000 times faster computing speeds compared to traditional CPUs. Furthermore, the growing uptake of sensors including high-resolution cameras, LiDARs, and ultrasonic sensors for vehicle situational awareness is fueling the growth of AI hardware.

The context awareness segment is anticipated to register an impressive growth with a CAGR of over 35% from 2019 to 2026 due to the rapid proliferation of driver assistance solutions and semi-automated cruise control. Context awareness systems provide situational intelligence through multi-sensory input and enable onboard computers to detect & classify on-road entities including pedestrians, traffic, and road infrastructure. Customers are reaping the benefits of context-awareness systems by deploying effective navigation assistance, which enables safe driving even during driver distraction. Major technology companies are investing in innovative automotive technologies including context awareness. For instance, in November 2016, Intel announced an investment of USD 250 million in autonomous driving technology. This investment was focused on key technologies such as context awareness, deep learning, security, and connectivity.

The image/signal recognition segment held majority of the market with over 65% share in 2019 due to the growing importance of vehicle speed control for reducing on-road accidents. Image/signal recognition technologies can detect traffic signs & speed limit indicators and reduce the vehicle speed accordingly without human intervention. The technology is also expected to grow significantly as several government initiatives are promoting traffic sign recognition to ensure adherence to speed limits. In March 2019, the European Commission made it mandatory for all vehicles manufactured from 2022 to have built-in image/signal recognition capabilities. This is expected to reduce rash driving, over-speeding, and promote on-road safety.

The semi-autonomous vehicles segment will grow at an impressive CAGR of over 38% by 2026 due to the extensive demand for Advanced Driver Assistance Systems (ADAS) and facilitating driving during heavy traffic scenarios. Semi-autonomous technologies have already been commercialized and are expected to gain significant market proliferation over the forecast timespan. Major automotive manufacturers, such as Chrysler, Audi, and Ford, have started integrating semi-autopilot and drive cruise control technologies into their latest models. Driver behavior monitoring, road condition awareness, and lane tracking are a few of the innovative solutions that have been introduced through the implementation of AI technologies in semi-autonomous vehicles. Furthermore, supporting initiatives from various governments to incorporate semi-autonomous vehicle technologies by 2022 will positively impact industry growth.

Europe held majority of the market with over 35% share in 2019 due to the growing demand for autonomous technologies in the region. Presence of several industry leaders including BMW, Audi, Mercedes, Daimler, and Bentley accelerated the advancements in autonomous mobility including several successful trial runs of level-5 autonomous vehicles. The increasing focus of automotive manufacturers on AI technologies, especially in Germany and the UK is driving the adoption of AI across the Europe automotive sector. Supportive initiatives from the government to adopt AI for smart traffic control has propelled the development of automotive AI solutions. In 2017, the UK government invested more than USD 75 million for the development of AI solutions and improved mobility.

Companies operating in AI in automotive market are focusing on various business growth strategies including investments in autonomous mobility solutions, strengthening partner network, and expanding R&D activities. Through such strategic moves, companies are trying to gain a broader market share and maintain their leadership in the market. For instance, in September 2019, Daimler partnered with Torc Robotics, an automated mobility firm, to design and develop level-4 autonomous trucks. Under the partnership, the companies are jointly testing autonomous trucks in the U.S. and focusing on evolving automated driving for heavy-duty vehicles.

Major Highlights from Table of contents are listed below for quick lookup into Artificial Intelligence (AI) in Automotive Market report

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Artificial Intelligence (AI) in Automotive Industry Insights

Chapter 4. Company Profiles

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/24675

See the rest here:

Artificial Intelligence (AI) in Automotive - Market Share Analysis and Research Report by 2025 - CueReport

Global Testosterone Replacement Therapy Market Size, Growth & Trends Analysis, Forecast 2020-2024 Research Report (Including COVID19 Impact…

Global Testosterone Replacement Therapy Market Report is an objective and comprehensive study of the current state expected at the major drivers, market strategies, and key vendors growth. The study also includes the important achievements of the market, Research & development and regional growth of the leading competitors operating in the market.

This report also explain the numerous factors that form a significant element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

Get Free Sample Report(including full TOC, Tables and Figures): @

https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#request_sample

Leading players of Testosterone Replacement Therapy Market:

AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Global Testosterone Replacement Therapy Geographical Segmentation Includes:

The research report includes an exploration of the competitive landscape present in the global Testosterone Replacement Therapy Market. It includes an impost of the current and future trends that players can invest in. Likewise, it also includes an estimation of the business outlooks of the players and explains the nature of the competition.

Hurry up to get huge discount:

Note: Upto 30% Discount: Get this reports in Discounted Price

Ask For Discount: https://www.globalmarketers.biz/discount_inquiry/discount/129647

Global Testosterone Replacement Therapy Market Segmentation

Global Testosterone Replacement Therapy Market Segmentation: By Types

GelsInjectionsPatchesOther

Global Testosterone Replacement Therapy Market Segmentation: By Applications

HospitalsClinicsOthers

The plus point of this research study is that it includes the impact ofCOVID-19to the Testosterone Replacement Therapy market. The data summarized within this research study includes forecast from 2019 to 2024. COVID-19 has significantly impacted each and every market on the global platform. If you have any specific requirement then Please get in touch with us. Our Expert team will provide as per report customized to your requirement.

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected]

https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#inquiry_before_buying

Important Features of the report:

Detailed analysis of the Testosterone Replacement Therapy market

Changing market dynamics of the trade

Comprehensive market segmentation

Historical, present and expected market size in terms of volume and value

Current business trends and developments

Testosterone Replacement Therapy Market Modest landscape of the market

Plans of key players and product offerings

A neutral view towards market performance

Reasons for buying this report:

It compromises an analysis of moving competitive scenario.

For making up-to-date decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers a Six-year assessment of the Global Testosterone Replacement Therapy

It supports in sympathetic the major key product segments.

It offers the regional analysis of the Global Testosterone Replacement Therapy Market along with the business profiles of several stakeholders.

It offers huge data about trending factors that will impact the progress of the Global Testosterone Replacement Therapy

Some Major TOC Points:

Chapter 1. Testosterone Replacement Therapy Market Report Overview

Chapter 2. Global Testosterone Replacement Therapy industry Growing Trends

Chapter 3. Market Share by Key vendors

Chapter 4. Testosterone Replacement Therapy Market Breakdown Data by Type and Application

Chapter 5. Testosterone Replacement Therapy Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Testosterone Replacement Therapy Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Factors

And Many More

Table of Content & Table Of Figures

https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#table_of_contents

View original post here:
Global Testosterone Replacement Therapy Market Size, Growth & Trends Analysis, Forecast 2020-2024 Research Report (Including COVID19 Impact...

ADA’s 30th anniversary marks progress for disabled Americans, but there’s still work to be done – Omaha World-Herald

Finding a job is also an issue. Rodgers went back to college and got certified to work on computers, but he says potential employers dont want to be liable for his medical issues.

I cant get any companies to hire me, mainly because of my health, he said. That needs to be addressed.

Warner noted that many disabled individuals also worry about taking a full-time job because that can mean losing public benefits such as health insurance or Social Security payments.

Im glad for what we do have, as far as being able to be out in the community and gain access to commerce, but I do believe there are further steps that could be taken, Warner said.

Improving work opportunities for the disabled has been a focus for Harkin since he retired from the Senate in 2015. He has urged companies to overhaul training programs and do whatever else is necessary to increase their hiring of disabled Americans.

Congress could help by passing legislation that would address the issue of disabled individuals losing benefits if they find full-time employment, he said.

Sen. Tom Harkin participated in events this week marking the 30th anniversary of the ADA, including a plane ride on Friday. The first armless pilot, Jessica Cox shown with him in the plane was at the controls.

Of the various ADA anniversary events Harkin joined this week, he said the most fun was a plane ride Friday with the first armless pilot, Jessica Cox, at the controls.

The two met through her advocacy work on the United Nations Convention on the Rights of Persons with Disabilities treaty, which they both continue to push.

More here:

ADA's 30th anniversary marks progress for disabled Americans, but there's still work to be done - Omaha World-Herald

Progress still hampered by battles on the fringes – McMinnville News-Register

Wednesday night, Portland Mayor Ted Wheeler, also the citys police commissioner, was simultaneously being gassed by federal agents and berated by protesters cursing his name, labeling his appearance at the 56th night of protest nothing more than a photo opportunity.

The videos of federal agents dispatched by the president gassing moms and clubbing veterans simply wanting to hold a conversation are abhorrent. While the agents have legal standing to protect the federal courthouse, the tactics administered have rightfully sparked a national outcry against a militarized federal government engaging in street clashes against its citizens. It is indeed a radical response from the U.S. Executive Branch, and likely more about politics than law and order as an election nears.

But its also not a surprising occurrence in Portland, where fringe activists have historically been allowed too much leeway to ruin the pure demonstrations for First Amendment rights amid honest attempts at progress.

To quote from a 2017 editorial in this newspaper:

Whether its Republicans on the right or Democrats on the left, allowing the most radical elements of their bases to compromise their principles and mute their voices is repugnant. It helps tighten the grip of raw partisanship, thus serving to thwart reasonable policy initiatives. ...

But when black-masked anarchists infiltrated the otherwise peaceful Portland demonstrations to pelt police, set blazes, smash windows, snarl traffic and engage in random acts of mayhem, organizers were more critical of the police for restoring order than the anarchists for disrupting it. ...

The anarchists were aided and abetted by then-Mayor Charlie Hales, who established a virtually unmatched record of ineptitude during his mercifully brief tenure. They got another boost when the district attorneys office dismissed charges against virtually all the 113 arrested.

Mayoral successor Ted Wheeler, displaying an equal lack of fortitude, allowed the anarchist fringe to bring city council meetings to a grinding halt for weeks with ceaseless demands for the police chiefs ouster. And it took nothing more than an anonymous threat for Portland anarchists to force cancellation of this years 82nd Avenue of Roses Parade.

It should have come as no surprise when anarchists began tossing Molotov cocktails, setting bonfires, defacing storefronts, shattering windows and pelting police again during the union movements annual May Day Parade, staged May 1 in Portland. After all, they openly recruited participants on social media sites.

But the response from the self-proclaimed voice of the American worker was, distressingly, a condemnation of the police rather than the bomb-throwers who spoiled the party and soiled the cause.

Those following the 50-plus days of protests in Portland this summer know they have been mostly peaceful and lawful. The righteous indignation of systematic racism and police brutality is warranted and deserving of cognitive discourse leading to legislation.

But the ongoing inability or unwillingness on both sides to filter extremist views has lead to a fictitious narrative, to the point where all cops are bastards and hundreds of moms wearing yellow are nothing more than Antifa in a new outfit.

With a subsection of protesters and a president eager to fan the flames of the ongoing urban warfare, as Wheeler described what he felt Wednesday night, it is difficult to find hope in positive reconciliation. But find hope, we must.

Read the rest here:

Progress still hampered by battles on the fringes - McMinnville News-Register

Forward progress stopped on Topsy Fire – The Record-Courier

As of 6 p.m. forward progress on a 25-30-acre fire burning between homes and watershed on Topsy Lane.

Set by lightning around 4 p.m. the fire resulted in Topsy Lane east of Highway 395 being closed.

Firefighters say two outbuildings have been lost with damage to one home.

Smoke reduced visibility on Highway 395 for the evening commute.

1E8BF949-1874-45E9-9DB2-49623D449352

1431A6B2-6173-4DE3-9B71-F9E6CCFF3584

A1BD1E35-6FE8-464C-84F4-7BF143337641

8DB1462A-3296-4130-B77B-22F89F4933CC

14A03752-5CA1-4206-8AC0-8F95E522F07B

69334209-25C0-4E4C-95DF-2CC031D4D6C0

6C954552-69B4-491E-BA9F-8ACC9FDC268F

97DB675A-0C72-4D14-A713-A178BE52D7DD

C4C285D1-CDF4-4413-AECB-74F040B5CC2C

Show CaptionsHide Captions

East Fork Fire and Carson City Fire Department were called Thursday afternoon about 4:05 p.m. The fire was reported to be ready to jump Topsy Lane at 4:20 p.m.

Multiple fire engines and brush units are responding , structures are currently threatened.

Previous stories

At 3:36 p.m., Doppler radar was tracking a strong thunderstorm near Gardnerville.

This storm was nearly stationary, according to the National Weather Service.

Heavy rain with water covering usually dry stream beds and winds in excess of 40 mph will be possible with this storm.

At 3:36 p.m., Doppler radar was tracking a strong thunderstorm near Gardnerville.

This storm was nearly stationary, according to the National Weather Service.

Heavy rain with water covering usually dry stream beds and winds in excess of 40 mph will be possible with this storm.

Locations impacted include Johnson Lane and the Fish Springs area.

Excerpt from:

Forward progress stopped on Topsy Fire - The Record-Courier

Opinion: The secrets behind longevity HS Insider – Los Angeles Times

Throughout history, longevity and eternal life have been the ultimate goal of humanity. From the king of the ancient Chinese Qin dynasty to the European alchemists during the medieval age, countless people have devoted their lives to unveil the secrets of immortality.

Although none of such efforts have been proven to grant eternal life, nowadays, modern scientists succeeded to elongate the lifespan of simple organisms, such as worms and flies, by a considerable amount with meticulous manipulation of our genes. Among many of those studies, there have been three main methods that held their significance even in the human body.

Enzyme regulation

Most notably, the Scripps Research team discovered that the disruption of enzymatic pathways by small molecules can affect the lifespan of an organism. The team used Caenorhabditis elegans, a type of a roundworm, to test their hypothesis.

According to Benjamin Cravatt, Gilula Chair of Chemical Biology at Scripps Research, C.elegans worms were used for their experiment due to their relatively short lifespans (typically lives only a few weeks). Cravatts research involved about 100 compounds that were known to inhibit serine hydrolases in mammals.

In his experiment, Cravatt used each of the 100 molecules to block the enzymatic pathway and observed their effects on the lifespan of the C.elegans. When the team treated the worms that were 1 day into adulthood with the inhibiting compounds, they found that some of the compounds extended the average lifespan of the worm by at least 15%, according to Alice Chen, a graduate student in the Cravatt lab.

Chen elaborated that among the compounds, a carbamate compound called JZL 184, even extended the lifespan by 45% when treated at the optimal dose. Through further analysis, the team concluded that JZL 184 extended the worms lifespan by inhibiting fatty acid amide hydrolase 4(FAAH-4), which is known to break down a molecule called 2-AG, a molecule linked to aging in mammals.

Whats fascinating about this finding is that monoacylglycerol lipase was not present in C.elegans worms. MAGL usually breaks down the 2-AG molecules in mammals, but in the case of Chens experiment, FAAH-4 substituted the role of MAGL.

While the findings only apply to C.elegans worms as of now, the team stated that the FAAH-4 and 2-AG pathways will suggest a new path in extending human life.

Calorie Regulation

In addition, a research team led by David Sinclair, assistant professor of pathology at HMS, found that calorie regulation extends the lifespan of yeast cells. According to Sinclair, the PNC1 protein regulates a vitamin called nicotinamide, which is an inhibitor of the Sir2 molecule. Sinclair further hypothesized that since Sir2 typically extends the lifespan of yeast cells by stabilizing the ribosomal DNA, the regulation of nicotinamide, which is its inhibitor, will consequently prolong the organisms lifespan.

While the team believed that such a regulation process was initiated by the severe calorie restriction in yeast cells, they later discovered that calorie restriction had no impact on the Sir2 level. Thus, Sinclairs team tested the effect of the molecule NAD on PNC1 levels to confirm that NAD was responsible for altering the Sir2 level. It turned out: NAD had no effect on the PNC1 level.

Undeterred, with more in-depth analysis, the team finally reached the conclusion that nicotinamide, which is one of the products of the reaction between Sir2 and NAD, was responsible for the change in Sir2 level. Based on the correlation they found between Sir2 level and nicotinamide facilitated by calorie restriction, Sinclairs team is now investigating human genes that play the same role as PNC1, according to Harvard Medical School.

Mifepristone

Finally, the research team led by John Tower, professor of biological sciences at the University of Southern California, found that the drug mifepristone extends the lives of female flies that have mated.

Before the experiment, Tower had set a premise that the sex peptide in female flies from male flies reduces the lifespan of the female flies as it causes inflammation. In his study, he and his colleagues discovered that the drug mifepristone, also called RU-486, blocked the effects of the sex peptide during reproduction, which retained the female flies health and thus extended their lifespan.

What played the most significant role in the reaction was, according to Tower, a molecule called the Juvenile hormone.

According to Towers research team, the juvenile hormone is responsible for the growth and development of fruit flies throughout their life. The sex peptide, they elaborated, boosts the effect of the juvenile hormone, which causes harmful inflammation in the flies body and enervates the male flies by shifting the metabolic pathways.

Therefore, the inhibition of the sex peptide by mifepristone also regulates the level of juvenile hormone, consequently extending the lifespan of the flies. With their further testing of the drug on C.elegans, which has similar genes as those of humans, Tower suggested that their findings may be applicable to extending the lives of humans.

The life-extending technology is still in its burgeoning stage, as it only applies to simple organisms, such as worms and flies. However, while eternal life still seems improbable, humanity will proceed one step further to unveiling the secrets of longevity with scientists perpetual efforts.

Read more:

Opinion: The secrets behind longevity HS Insider - Los Angeles Times

Air Force awards contracts to develop Skyborg combat drones that ‘learn’ how to fight – Stars and Stripes

Four companies have been chosen to develop combat drones that will use artificial intelligence to either fully execute or support manned aircraft on strenuous or dangerous missions, the Air Force said.

Boeing, Northrop Grumman, General Atomics and Kratos Unmanned Aerial Systems were awarded contracts in support of the Air Forces Skyborg Vanguard Program, the Air Force Life Cycle Management Center said in a statement Thursday. The companies will compete for up to $400 million in orders, it said.

The program name evokes the cyborg man-machine hybrids of science fiction, but also perhaps the fictional artificial intelligence network Skynet in the Terminator film series.

Will Roper, the Air Forces assistant secretary for acquisition, technology and logistics, suggested a more endearing fictional creation, Defense News reported. At a conference last year, he likened it to the beep-booping droid R2-D2 of the Star Wars universe that helps Luke Skywalker and his father pilot their fighter spacecraft.

The real-world drones are supposed to include AI upgrades to allow them to learn how to engage enemy defense systems, as well as to share data with manned F-35 and F-15 fighters. This would allow the drones to operate in tandem with the jets in a wingman role, officials said.

Because autonomous systems can support missions that are too strenuous or dangerous for manned crews, Skyborg can increase capability significantly and be a force multiplier, Brig. Gen. Dale White, program executive officer for fighters and advanced aircraft, said in the statement. We have the opportunity to transform our warfighting capabilities and change the way we fight and employ air power.

The new drones, which will eventually replace the MQ-9 Reaper, will be designed to be attritable, meaning they will be inexpensive enough that losing one in combat would be tolerable.

The first Skyborg drones are expected to be operational by 2023. At least two models a ground attack and an air superiority version are expected to be fielded, according to Aviation Week & Space Technology.

The U.S. is not the only country developing stealthy combat drones, although its not clear whether any others are AI-enabled.

In October, China featured a prototype of the GJ-11 Sharp Sword drone at its national day parade. Russia, meanwhile, has released video of a much larger Sukhoi Su-70 drone flying in formation with an Su-35 fighter, indicating that the two are capable of operating in tandem.

And Israel has already used in Syria a stealth loitering drone that can crash into targets if its detected, or return to base if the strike is called off.

lekic.slobodan@stripes.com

A Skyborg conceptual design for a low-cost, unmanned combat drone. Four companies have been picked to build the Air Force's Skyborg drone, the Air Force Life Cycle Management Center said in a statement on July 23, 2020.AIR FORCE RESEARCH LABORATORY

article continues below

See the original post:

Air Force awards contracts to develop Skyborg combat drones that 'learn' how to fight - Stars and Stripes

The Knicks are reportedly hiring Tom Thibodeau and Knicks Twitter lost it – For The Win

Theres always some sort of drama or controversy with the New York Knicks and their fans. If its not one thing, its the other.

On Saturday, it was their coaching hire. The Knicks are moving forward to make former Bulls and Timberwolves head coach Tom Thibodeau their next head coach, according to a report from ESPNs Adrian Wojnarowski.

The two sides are in the middle of hammering out the final details on a contract that would keep Thibodeau in New York for the next five years. It will be on him to shape the prime of R.J. Barrett and Mitchell Robinsons careers.

You can already hear the sound of creaking knees in the background just reading that tweet.

The Knicks are in a unique space. Theyve got a ton of young talent on that team starting with Barrett and Robinson. They needed a coach who could help bring out their best while also shaping their future.

And Thibodeau definitely has one part of that down. Lets, uh, leave the Timberwolves aside for a sec. He coached Derrick Rose to an MVP season, turned Jimmy Butler and Luol Deng into All-Stars and turned Joakim Noah into a Defensive Player of the Year.

On the other hand? He ran also ran pretty much all of them into the ground Jimmy Butler is an exception because hes a cyborg.

Thibodeau is known to grind his players away with heavy minutes and that concerns a lot of Knicks fans.

The jokes were pretty funny, though.

Its all good, Knicks fans. There are a couple of silver linings, at least! First, at least its not Jason Kidd. Second, we get to use this Vine again!

Ah, yes. Everything comes full circle. Finally.

Go here to see the original:

The Knicks are reportedly hiring Tom Thibodeau and Knicks Twitter lost it - For The Win

Prepare for four more years of the most disruptive president ever – MSN Money

Getty Images Prepare for four more years of the most disruptive president ever

You would be hard-pressed to find anyone who doesn't harbor incredibly strong feelings about President Trump. Millions of Americans hate him. Millions still support him. "I don't have an opinion about Trump" is not something you'd expect to hear in a casual or political discussion - which is precisely the point.

For decades, Trump has been a lightning rod attracting the electrical discharges of hate and admiration with little neutral voltage in between. After he beat Hillary Clinton in 2016, he began to get zapped by hundreds of thousands of opinionated charges, and then literally millions, emanating from around the globe.

Today we could say these charges have become "matter versus antimatter," creating a dangerous energy field that may not be able to be shut down regardless of the outcome of November's presidential election.

In a speech at the American Enterprise Institute's annual dinner last year, Nikki Haley, a former U.N. ambassador and former South Carolina governor who is still a powerful voice in the GOP, cut to the chase regarding Trump: "President Trump is a disruptor. That makes some people very happy, and it makes some people very mad." She is correct - the president is a disruptor, and the need to disrupt likely is in his DNA. Our nation and the world haven't experienced another president like him.

Forget "The Art of the Deal," the book that introduced many Americans to Trump. For the past five decades, he has used "the art of disruption" to break down seemingly insurmountable walls to achieve his goals. Many times, he succeeded. Sometimes, the bricks and mortar collapsed upon him.

But even when they caved, he crawled out, dusted himself off and went about disrupting the next obstacle in his path. Those who have come to hate Trump must think they are watching a never-ending, real-life version of the "The Terminator," with Trump playing the role of the unstoppable cyborg.

Since Haley made her remarks last November, the world has been turned on its head by a deadly pandemic and our nation has been disrupted by legitimate protests and civil unrest tinged with troubling violence.

But through it all, Trump remains virtually the same. What you see is what you get. He's still that one-man disruptive force of often epic proportions. He goes full speed ahead - damn the (rhetorical) torpedoes!

Most media appear to be left of center in the U.S. and many other countries. They've come to truly loathe Trump and made their low opinions of him abundantly clear. Some world leaders and their staff have scoffed at the president too. Trump the disruptor, marching to his own beat, truly rubs them the wrong way. They want him gone.

On the other hand, the millions of voters in the U.S. who strongly support Trump need him to remain that disruptive force against both major political parties and the entrenched elite establishment. Power centers, they believe, never have had their best interests at heart.

As the election approaches, our nation is in a precarious and volatile position. Millions of Americans seem to be on the edge of despair - whether from the destructive fallout from the pandemic, its politicization, the ugly polarization of our politics or the pockets of anarchy.

The killing of George Floyd in Minneapolis was barbaric, and those who rose up in protest were right to do so; their voices need to be heard. But violence in the streets, destruction of property and calls to "defund the police" are deeply worrisome to many Americans. Such anarchy goes too far even for some Democrats, liberals and minority communities. No one wants violence in their neighborhood, town or city, especially Americans who may be struggling to survive.

Against this backdrop, voters will be asked to choose between our disruptive president or tentative former Vice President Joe Biden. I wonder if Democrats privately have confidence in the polls showing Biden leading Trump - or confidence in Biden himself.

But if the storms continue to rage, I suspect enough voters - frightened by the anarchy and nervous about the reversal of course sought by some on the left - will choose to ride it out with Trump until 2024. Then, they'll take a deep breath, collect their thoughts and elect America's first female president.

Douglas MacKinnon was a writer in the White House for Presidents Ronald Reagan and George H.W. Bush, and former special assistant for policy and communication at the Pentagon during the last three years of the Bush administration. He is the author of: "The Dawn of a Nazi Moon: Book One."

The rest is here:

Prepare for four more years of the most disruptive president ever - MSN Money

The X-Men’s Most Unstable Team Is Killing Each Other – Screen Rant

The X-Men started the Hellions hoping it would be a superhero therapy group... but therapy doesn't usually involve mutant guns and chest blasts.

Spoilers for Hellions #2!

The X-Men have been feeling experimental since the start of the Dawn of X relaunch, and their latest attempt at making the lives of mutants better is not going well. The ruling body of the mutant nation Krakoa, the Quiet Council, put together a team of unpredictable, antisocial, even villainous mutants, then tasked them with performing missions that the Council felt would be cathartic and productive. They called that team the Hellions. InHellions #2, the therapeutic superhero squad takes on their first mission... to zero success and lots of violence between teammates.

Hellionsis written by Zeb Wells, illustrated by Stephen Segovia, and colored by David Curiel. The team roster mixes popular X-Men heroes with classic and obscure villains, all under the banner of the new mutant cause of Krakoa and its belief that even the team's worst villainscan find clemency there. The current roster includes Cyclops' brother Havok, psychic ninja Psylocke, feral fighter Wild Child, indoctrinated soldier Orphan-Maker and his protectivecyborg Nanny, emotional manipulator Empath, and techno-shapeshifter Greycrow, with the supervision of mad geneticist Mister Sinister.

Related: X-MEN Theory: Mystique Is X of Swords' Secret Villain

In Hellions #2, the teamsets out to destroy an old lab of Sinisters located beneath a now-abandoned orphanage that Sinister once used as a cover to obtain experimental subjects. Much of the team has ties to Sinister and his baby-snatching operation, and tensions are immediately high. Wild Child attacks a police officer with a K-9 companion in an instinctive effort to become the pack leader.Havok, who grew up there, insists he doesn't belong with the traumatized crew, but Psylocke senses his anxiety is loudest of all since he grew up there under Sinisters' testing schedule.

When Empath decides to blow off steam by nudging Nanny into a frenzy of protective worry, she latches onto Greycrow as if he's a waywardchild. Greycrow doesn't find it funny; he shoots Empath in the head. Since the X-Men have effectively conquered death, this is a matter of paperwork rather than a permanent loss. But stakes get higher the further they delve into the lab, and the team doesn't get any more cohesive.

The real violence begins when the team discovers that diabolical witch Madelyne Pryor has taken up residence in the lab and has been growing half-mindless mutant soldiers from Sinister's leftover, half-fried genetic samples. The enemy mutants may not be highly skilledcombatants, but Madelyne sends each one to fight a Hellion they're perfectly suited to disable. While the others fall, Pryor approaches Havok personally and reminds him of their past romantic history, which leaves him mesmerized enough to leave with her. As her zombifiedclones drag the dead and incapacitatedHellions away, the only two who remain are Psylocke and Wild Child... who sees that the ninja pack leader is wounded and weak, and goes in for the kill.

Hellions is only two issues in and the kinks have clearly yet to be worked out of this roster. Still, since most of the roster is dead, MIA, or trying to kill each other, it might be time to have a long talk between Xavier, Sinister, and--if he ever returns--Havok about the viabilityof this shooting-and-stabbing-based therapy program. Have theQuiet Council given any thought to art therapy? Role-playing? A villains-only dance studio?

Hellions #2is available now from Marvel Comics.

More:The X-Men Typo That Turned Cyclops Into A 'Furry'

Batman Will Finally Face His FIRST Rival, Ghost-Maker

Sean Finley is a comics news writer for ScreenRant. Mutated as a child by a radioactive copy of Amazing Fantasy #15, he now contributes articles, reviews, and short fiction to local and online outlets using a variety of thematic personas. When he isn't writing, he's the forever DM for his local D&D group, where everything is made up and the points don't matter. You can reach him at wseanfinley (at) gmail.com.

Link:

The X-Men's Most Unstable Team Is Killing Each Other - Screen Rant

Massive Growth in Animal Stem Cell Therapy Market Breaking new grounds and touch new level in Upcoming Year by VETSTEM BIOPHARMA, MediVet Biologic,…

Animal Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=134420

Key Players Profiled in This Report:

VETSTEM BIOPHARMA, MediVet Biologic, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Get 20% Discount on this Premium Report at:

https://www.a2zmarketresearch.com/discount?reportId=134420

Reasons for buying this report:

Table of Contents:

Global Animal Stem Cell Therapy Market Research Report

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=134420

Go here to read the rest:

Massive Growth in Animal Stem Cell Therapy Market Breaking new grounds and touch new level in Upcoming Year by VETSTEM BIOPHARMA, MediVet Biologic,...

Stem Cell Therapy for Diabetes and Related Conditions Market analysis with Leading Key Players and Regional Analysis 2026 – CueReport

The Global Stem Cell Therapy for Diabetes and Related Conditions market report offers key information about the industry, helpful and important facts and figures, expert opinions, and the latest developments across the world. The research report represents a comprehensive presumption of the market and encloses imperative future estimations, industry-authenticated figures, and facts of the global market. It predicts inclinations and augmentation statistics with emphasis on abilities & technologies, markets & industries along with the variable market trends. The Stem Cell Therapy for Diabetes and Related Conditions market report analyses and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Stem Cell Therapy for Diabetes and Related Conditions market.

The Stem Cell Therapy for Diabetes and Related Conditions market report intends to offer significant information of this business space while elaborating on the key global trends. The document emphasizes on the growth opportunities as well as the drivers that will influence the profitability graph of this business vertical over the estimated timeframe. It also measures the challenges & restraints that may inhibit the expansion of the market.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25032

The research repot delivers a comparative statement regarding the existing and predicted market scenario to derive the growth rate of this industry vertical over the study duration. Additionally, it measures the effect of COVID-19 outbreak on the regional as well as overall market to denote the methodologies that can help in decision making.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25032

Major details from Table of Contents:

Product landscape

Application scope

Regional Analysis

Competitive arena

In short, the Stem Cell Therapy for Diabetes and Related Conditions market provides a granular assessment through numerous segmentations, while evaluating the other aspects including sales channel and supply chain processes which consist of downstream buyers, upstream suppliers, and distributors of this business space.

Key Answers Captured in Study Objectives are

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/25032

Continued here:

Stem Cell Therapy for Diabetes and Related Conditions Market analysis with Leading Key Players and Regional Analysis 2026 - CueReport

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model – PRNewswire

HOUSTON, July 21, 2020 /PRNewswire/ --FibroGenesis announced today new data supporting use of its PneumoBlast product in the battle against COVID-19.Using the widely accepted bleomycin model of lung scarring (fibrosis), Company scientists have demonstrated the administration and use of PneumoBlast induced a 51% reduction of lung fibrosis,which was statistically significant (p < .005). Importantly, when PneumoBlast was compared head to head with bone marrow derived mesenchymal stem cells (BMSCs) for COVID-19, PneumoBlast was 221% more effective. In producing the potent anti-inflammatory protein interleukin 1 receptor antagonist, which is believed to be the mechanism of scar tissue prevention by BMSC therapies currently in development, PneumoBlast was 192% more effective than BMSCs which was again, statistically significant(p < .005).

During an interview with Healthline.com, Dr. Lori Shah, transplant pulmonologist at New York-Presbyterian/Columbia University Irving Medical Center, stated "Holes in the lungs likely refers to an entity that has been dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory distress syndrome] fibrosis, which is irreversible and can result in severe functional limitations from patients, such as cough, shortness of breath, and need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through lung inflammation, but in some patients causes permanent lung injury through stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. "The prospects that our cell therapy approach not only possesses therapeutic effects on animal models of the acute stage of COVID-19, but also benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the biological and medical consequences of the COVID-19 infection, FibroGenesis is eager to contribute to the therapeutic cure options currently being created to fight this global war against an invisible enemy," commented Pete O'Heeron, President/CEO of FibroGenesis. "While we are excited about potential vaccines in the pipeline, the fact remains that there are 3.8 million confirmed cases of COVID-19 in the U.S. and we do not know what the long-term outcomes for these patients will be. To our knowledge, we are the only cell therapy company which is creating a therapy to resolve the initial pathology of infection and also proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

SOURCE FibroGenesis

http://www.Fibro-Genesis.com

Excerpt from:

COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - PRNewswire

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 – Owned

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.Use-type InsightsThe clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.TherapyType Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the original post here:

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Owned

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers – Technology Networks

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patients immune system to attack cancer. But immunotherapies dont work in all patients, and researchers have been searching for ways to increase their effectiveness.

Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia. Evidence also suggests that the new approach could be safer than one of the most recent cellular immunotherapies to be approved by the FDA, called CAR-T cell therapy, in which the immune systems T cells are engineered to target tumor cells. Cell-based immunotherapies are most commonly used against blood cancers but can be harnessed against some solid tumors as well, such as prostate and lung tumors and melanoma.

The study appears online in the journal Blood.

In the new research, the scientists have harnessed the technology used to engineer CAR-T cells and, instead of modifying specialized immune cells called T cells, they have used similar technology to alter different immune cells called natural killer (NK) cells. The resulting immunotherapy combines the benefits of both strategies and may reduce the side effects that are sometimes seen in CAR-T cell therapy. In some patients, for example, CAR-T cell therapy causes a cytokine storm, a life-threatening overreaction of the immune system.

Immunotherapies show great promise for cancer therapy, but we need to make them more effective and more safe for more patients, said co-senior authorTodd A. Fehniger, MD, PhD, a professor of medicine. This combined approach builds on the treatment strategy that we developed for leukemia patients using natural killer cells. We can supercharge natural killer cells to enhance their ability to attack cancer cells. And at the same time, we can use the genetic engineering approaches of CAR cell therapy to direct the natural killer cells to a tumor target that would normally be overlooked by NK cells. It fundamentally changes the types of cancer that NK cells could be used to treat, both additional blood cancers and potentially solid tumors as well.

In past work, Fehniger and his colleagues showed that they could collect a patients own NK cells, expose the cells to a specific recipe of chemical signals that prime the cells to attack tumors, and then return the primed cells to patients for therapy. This chemical exposure is a sort of basic training for the cells, according to the investigators, preparing the NK cells to fight the cancer. When the cells are then returned to the body, they remember their training, so to speak, and are more effective at targeting the tumor cells. Because their training has given the NK cells a memory of what to do when they encounter tumor cells, the researchers dubbed them memory-like NK cells.

In small clinical trials conducted atSiteman Cancer Centerat Barnes-Jewish Hospital and Washington University School of Medicine, such cells were effective in putting some patients with leukemia into a lasting remission, but they didnt work for everyone. Some tumor cells still evaded the memory-like NK cells, despite the cells basic training. To help the cells find the tumor cells, so their basic training can kick in and kill the correct target, the researchers modified the memory-like NK cells with the same CAR (chimeric antigen receptor) molecule that is typically used to target T cells to tumor cells. The CAR molecule is flexible and can be modified to direct the cells to different tumor types, depending on the proteins on the surfaces of the cancer cells.

The resulting hybrid cells were more effective in treating mice with leukemia than memory-like NK cells alone, leading to longer survival for mice treated with CAR memory-like NK cells. The researchers also found the therapy to be effective despite the fact that the mice were given relatively low doses of the cells.

One aspect of this study I find most exciting is how nicely these hybrid NK cells expand in the mice to respond to their tumors, said co-senior authorMelissa Berrien-Elliott, PhD, an instructor in medicine. We can provide a tiny dose and see an incredible amount of tumor control. To me, this highlights the potency of these cells, as well as their potential to expand once in the body, which is critical for translating these findings to the clinic.

Fehniger also pointed out that an advantage of NK cells in general and for biological reasons that the scientists are still working to understand NK cells dont trigger a dangerous immune response or the long-term side effects that T-cell therapy can cause in attacking the patients healthy tissues, a condition called graft-versus-host disease.

In all of the clinical trials exploring any type of NK cells, we dont see the troublesome side effects of cytokine release syndrome or neurotoxicity that we see with CAR-T cells that can profoundly affect patients, Fehniger said. These side effects can be life-threatening and require intensive care. Were still working to understand how NK cells are different. But if you can get the benefits of CAR-T cells with few if any of the side effects, thats a reasonable line of research to pursue. Another benefit of this safer therapy is the potential to give these cells to patients at an earlier stage in their disease, rather than using them as a last resort.

Other groups have developed CAR-NK cells, but a major difference is that other groups NK cells came from donated cord blood or induced stem cells, rather than adult donors or the patients themselves.

The other groups have artificially differentiated stem cells into something that resembles an NK cell, Fehniger said. With that strategy, theres no guarantee that those cells will have all the properties of typical mature NK cells. In contrast, were starting with adult NK cells, so were more confident that they will have all the inherent properties and behavior of adult NK cells, which we have already shown to be effective in certain types of cancer patients, especially those with leukemia. Inducing memory properties adds to their persistence and effectiveness against many cancer types.

Over the next several years, we would like to be able to scale up this process to produce enough cells for a first-in-human clinical trial, and investigate their effectiveness in different types of human blood cancers, he said.

Reference: Gang, et al. (2020). CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. DOI: https://doi.org/10.1182/blood.2020006619

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers - Technology Networks

Researchers ID new target in drive to improve immunotherapy for cancer – UCLA Newsroom

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistryhave identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.

A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity.

BACKGROUND

Immunotherapies using PD1 blockade have transformed the way people with difficult cancers are treated. Currently, PD1 blockade combined with chemotherapy is approved for recurrent or metastatic head and neck cancer, giving people whose disease would have otherwise been seen as a death sentence another option. However, response rates are not very high and response duration is relatively short, indicating that this type of cancer might be resistant to PD1 blockade.

To help overcome immunotherapy resistance, UCLA researchers have been studying the role of cancer stem cells and the protein BMI1. Growing evidence suggests cancer stem cells might be responsible for such resistance, as well as for relapse or reoccurrence, and BMI1, which functions in several cancers, including head and neck, has been found to control cancer stem cells self-renewal. Targeting cancer stem cells may be critical for improving the efficacy of immunotherapy and preventing tumor relapse.

METHOD

The team used a mouse model of head and neck squamous cell carcinoma that fully mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. They then tested whether BMI1 cancer stem cells could be eradicated by PD1 blockadebased combination therapy using both pharmacological and genetic inhibition of BMI1. They found that inhibiting BMI1 not only helped eliminate the BMI1 cancer stem cells but also enhanced PD1 blockade by activating tumor cellintrinsic immunity, which inhibited metastatic tumor growth and prevented tumor relapse.

IMPACT

Many people with advanced head and neck cancers who are treated with PD1 blockade and chemotherapy eventually see their cancer return and become resistant to the therapy. This preclinical study provides an important foundation for developing a new PD1 blockadebased combination therapy with BMI1 inhibitors that have the potential to help overcome resistance to the immunotherapy.

AUTHORS

The senior author is Dr. Cun-Yu Wang, professor and chair of oral biology at the UCLA School of Dentistry and a member of the UCLAs Jonsson Comprehensive Cancer Center, Samueli School of Engineering and Broad Stem Cell Research Center. The lead author is Lingfei Jia, an assistant project scientist in oral biology at the School of Dentistry and Jonsson Cancer Center. Wuchang Zhang, an assistant project scientist in oral biology, is also an author.

JOURNAL

The study ispublished onlinein the journal Cell Stem Cell.

FUNDING

The work was supported by grants from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.

See original here:

Researchers ID new target in drive to improve immunotherapy for cancer - UCLA Newsroom

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy – DocWire News

This article was originally published here

Stem Cell Rev Rep. 2020 Jul 21. doi: 10.1007/s12015-020-10004-x. Online ahead of print.

ABSTRACT

Nearly 500000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents antiviral and anti-inflammatory molecules have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease.

PMID:32696426 | DOI:10.1007/s12015-020-10004-x

View original post here:

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy - DocWire News

Trending News on Targeted Oncology, Week of July 24, 2020 – Targeted Oncology

In oncology news this week, the FDA accepted a supplemental New Drug Application for selinexor(Xpovio) as treatment of patients with relapsed or refractory multiple myeloma who had received at least 1 prior line of therapy. Meanwhile, theFDA granted clearance for the cancer drug abivertinib to be investigated in a phase 2 study as treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).

This week Targeted Oncology hosted a tweet chat with Alexander N. Shoushtari, MD, of Memorial Sloan Kettering Cancer Center, to discussion the case of a 52-year-old woman withBRAF-mutant metastatic melanoma. Following the tweet chat, Shoushtari continued the discussion in an interview.

Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML

The risk of relapse or death was reduced by 61% with the use of sorafenib maintenance therapy compared with placebo following allogeneic hematopoietic stem cell transplantation in patients withFLT3-ITDpositive acute myeloid leukemia, according to the results of the phase 2 SORMAIN trial.

Ruxolitinib Reduces Spleen Size in Patients With Myelofibrosis and Low-Platelet Counts

Ruxolitinib, the JAK1/2 inhibitor, induced significant spleen responses in patients with myelofibrosis, both with general disease and in patients with low platelet counts, according to results from the phase 3b JUMP study.

Pivotal Phase 3 Trial Initiated to Study Promising Cabozantinib/Atezolizumab Combo in Advanced RCC

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

CLR 131 Induces Encouraging Responses in Relapsed/Refractory LPL and WM

CLR 131 induced an objective response rate of 100% as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenstrms macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

Avelumab Plus TG4001 Shows Promising Efficacy in HPV16-Positive Metastatic Cancers

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies, a phase 1b/2 clinical trial showed.

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia in this episode of Targeted Oncology Case Based Peer Perspectives series.

Analyzing the Importance of Biomarker Testing and MSI Status in mCRC

Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate 142 trial.

Limited Toxicity Seen With Leronlimab in Mild to Moderate COVID-19

Treatment with leronlimab in patients with mild to moderate symptoms of respiratory illness from COVID-19 caused fewer serious adverse events when compared with placebo, according to safety results from a phase 2 clinical trial.

Study Shows Disparities, Effects of Treatment for Patients With Cancer and COVID-19

Data from a treatment utilization study revealed racial disparities in treatments for COVID-19 as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with COVID-19.

Go here to see the original:

Trending News on Targeted Oncology, Week of July 24, 2020 - Targeted Oncology